PET agent flutemetamol shows promise for Alzheimer's detection

04/11/2012 | (free registration)

GE Healthcare said initial results from two Phase III trials are promising for flutemetamol, an experimental PET imaging agent for Alzheimer's disease. In one study, findings on PET correlate with brain-autopsy data. In the other study, results are consistent with a known lack of brain amyloid in patients.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI